According to information from Dr. Schilz, the BioNTech sites were examined, with the result that overcapacities have built up in the Group network, which are now being consolidated. This also affects the Idar-Oberstein site, which focuses on the production of mRNA and cell and gene therapeutics in early clinical development as well as analytics and quality control for the Pfizer-BioNTech COVID-19 vaccine. BioNTech is currently exploring the possibility of selling the site in Idar-Oberstein. BioNTech intends to implement the measures in a socially responsible manner - if possible without compulsory redundancies through a completed program for those affected.
"This news is of course initially bad news for the affected employees and their families," explains Lord Mayor Frank Frühauf. However, the loss of jobs also means a weakening of Idar-Oberstein as a business location and of the entire region. "These are high-quality jobs that are at risk," says Frühauf. However, the mayor hopes that a buyer will be found for the site. "The site has first-class laboratories with high safety levels and highly qualified specialists," emphasizes Mayor Frühauf. The current BioNTech laboratories, in which the Group has recently invested heavily, were first occupied by EUFETS and then by Fresenius Medical Care with research facilities. Mayor Frühauf is therefore confident that a suitable successor use can be found. "Of course, the city would welcome and strongly support such a relocation."